<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Medical cannabis: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Medical cannabis: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Medical cannabis: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F56544395"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Cannabinoid</li></ul></div>
<div class="block doa drugH1Div" id="F56544597"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>No specific dose recommendations exist due to differences in preparations and routes of administration; for example, vaping cartridges containing cannabis products may deliver higher doses more efficiently as compared to smoking herbal cannabis products (Davenport 2021). In addition, there is wide variability between patients with regards to response to cannabinoids; treatment regimens must be patient-specific and accompanied by close monitoring (Health Canada 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Inhalation, Oral, Sublingual:</b> In general, clinicians are advised to initiate therapy at a low dose and utilize a slow titration schedule (Busse 2021; CFPC 2014). Consider repeated doses no sooner than every 10 to 20 minutes (inhalation) or ≥30 minutes (oral) to allow for impact of prior dose to be realized and to prevent overdose. Use caution when increasing daily dose; consider increase of 1 puff (inhalation) or 1 drop (sublingual) per dose per day (Health Canada 2018).</p></div>
<div class="block dora drugH1Div" id="F56544599"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling of FDA- or Health Canada–approved cannabidiol products (has not been studied); use with caution (Dronabinol prescribing information; Sativex Canadian product monograph; Syndros Canadian product monograph).</p></div>
<div class="block doha drugH1Div" id="F56544600"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment: Consider avoiding use in patients with moderate impairment (Sativex Canadian product monograph).</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use is not recommended in patients with severe liver disease (Health Canada 2018; Sativex Canadian product monograph).</p></div>
<div class="block dot drugH1Div" id="F56544601"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">Acute psychosis: Discontinue treatment and seek immediate medical attention (Health Canada 2018).</p></div>
<div class="block doe drugH1Div" id="F56544598"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Use with caution; older adults may be more sensitive or susceptible to adverse effects (Health Canada 2018).</p></div>
<div class="block adr drugH1Div" id="F56225935"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from limited sources (Health Canada 2018, Wang 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, atrial fibrillation, cerebrovascular accident, circulatory shock, deep vein thrombosis, hypertension, hypotension, orthostatic hypotension, orthostatic syncope, palpitations, supine hypertension, syncope, tachycardia, vasodilation, ventricular arrythmia, ventricular premature contractions</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis, hyperhidrosis, pressure ulcer, pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration, hot flash, increased thirst</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, constipation, decreased gastrointestinal motility, diarrhea, duodenal ulcer, dysgeusia, dysphagia, gastroenteritis, increased appetite, nausea, oral mucosa ulcer, pancreatitis, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Bladder dysfunction, hematuria, testicular neoplasm, urinary tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, leukopenia, lymphadenopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests, hepatic fibrosis, hepatobiliary disease (biliary cirrhosis), liver steatosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection, sepsis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams, aggressive behavior, agitation, amnesia, anxiety, apathy, ataxia, balance impairment, bipolar mood disorder, central nervous system depression, cognitive dysfunction (and altered perception), confusion, decreased mental acuity, delusion, depersonalization, depression (including a feeling of despair), disorientation, dissociative reaction, disturbance in attention, dizziness, drowsiness, drug dependence, dysarthria, dysphoria, emotional lability, euphoria, falling, fatigue, hallucination, headache, hypoesthesia, impulsivity, intoxicated feeling, irritability, lack of concentration, memory impairment (and cognitive impairment), mood changes, mouth pain, myasthenia, myoclonus, nervousness, panic attack, paranoid ideation, paresthesia, psychosis, schizophrenia, sedated state, seizure, speech disturbance, suicidal ideation, suicidal tendencies, vertigo, withdrawal syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia, muscle spasm, muscle twitching, myalgia, osteomyelitis, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, eye redness</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute pulmonary reaction (bronchodilation), cough, dyspnea, increased bronchial secretions, lower respiratory tract infection, nasopharyngitis, pharyngitis, pleural effusion, pleurisy, pneumonia, throat irritation, wheezing</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Aggravation reaction, drug tolerance, fever</p></div>
<div class="block coi drugH1Div" id="F56544568"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">In general, contraindications that apply to cannabinoid-based therapies (eg, nabilone, dronabinol) also apply to the use of all cannabis products (Health Canada 2018).</p></div>
<div class="block war drugH1Div" id="F56544569"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular and cerebrovascular effects: Delta-9-tetrahydrocannabinol (THC) may cause occasional hypotension, possible hypertension, syncope, or tachycardia; patients with cardiac disorders may be at higher risk for hemodynamic instability. Monitor for changes in heart rate, BP, and for signs/symptoms of syncope after initiating treatment and with dosage increases. Avoid concomitant use with other medications associated with similar cardiovascular adverse effects (Dronabinol prescribing information; Syndros Canadian product monograph). Inhalational use of cannabis may be a rare trigger of acute myocardial infarction and/or result in an increased risk of hospitalization for acute ischemic stroke (Mittleman 2001; Rumalla 2016). Use is not recommended in patients with a prior history of severe cardiovascular or cerebrovascular disease (Franz 2016; Health Canada 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression (including sedation and somnolence), which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving). Use with caution with concomitant use of sedative-hypnotics or other psychoactive drugs; concomitant use of alcohol may increase the risk for adverse events (Health Canada 2018). Consider counseling patients who have used cannabis to avoid driving for 4 hours following inhalation, 6 hours following oral ingestion, or 8 hours following inhalation or oral ingestion if the patient is experiencing euphoria (CFPC 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• E-cigarette, or vaping, product-use associated lung injury: Use of e-cigarette or vaping products has been associated with an outbreak of e-cigarette, or vaping, product-use associated lung injury (EVALI) (Ellington 2020). Epidemiologic data suggest that EVALI most often occurred in individuals who used THC-containing products obtained from informal sources. In patients who developed EVALI following use of THC-containing products during the 2019 outbreak, vitamin E acetate was often found in the vaping product; however, it is not known if other additives may also result in EVALI (Krishnasamy 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">• GI effects: New or worsening paradoxical nausea, vomiting, and/or abdominal pain has occurred with oral cannabinoid therapy; symptoms are similar to cannabinoid hyperemesis syndrome (CHS) (Dronabinol prescribing information; Syndros Canadian product monograph). CHS is generally associated with frequent (weekly or greater), chronic (≥1 year) use (Sorensen 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Use of cannabis may result in hypersensitivity regardless of the route of exposure. Symptoms may range from mild to life-threatening and may include respiratory symptoms following inhalation, as well as dermatologic reactions following handling. Use is not recommended in patients with a prior history of hypersensitivity to any cannabinoid or smoke (if cannabis will be smoked) (Health Canada 2018). Cross reactivity with plant-derived food allergies (cannabis-fruit/vegetable syndrome) may occur; the most commonly associated food allergies include peach, banana, apple, cherry, nuts, tomato, orange, and grapefruit (Decuyper 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: Current, frequent (weekly or greater), or chronic (≥10 years) use of cannabis may be associated with an increased risk of nonseminoma-type testicular cancer (Gurney 2015; Huang 2015). Although data are conflicted on the risk of carcinogenesis and mutagenesis secondary to smoking cannabis, it is recommended that smoking should be avoided as a preferred route of administration and other routes should be considered (Health Canada 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric effects: Use of cannabis, especially THC-predominant products, may be associated with an increased risk of psychosis and schizophrenia (Hindley 2020); early, chronic, and heavy use of cannabis is associated with a higher risk (Health Canada 2018; Wilkinson 2014). Use is not recommended in patients with a personal history or strong family history of schizophrenia (CFPC 2014). Use of cannabis, especially THC-predominant products, may also be associated with the onset of anxiety, depressive, and bipolar disorders as well as the exacerbation of symptoms related to posttraumatic stress, panic, depressive, and bipolar disorders (Health Canada 2018; Volkow 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory effects: Use of inhaled cannabis, especially chronic use, is associated with inflammation of the large airways, increased airway resistance, lung hyperinflation, and chronic bronchitis (Tashkin 2013). Use of inhaled cannabis is not recommended in patients with a history of respiratory disease (eg, asthma, chronic obstructive pulmonary disease) (Health Canada 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Substance use disorder and dependence: Chronic use may lead to substance use disorder and/or dependence; risk is increased with onset of use during adolescence and prior history of substance abuse (Volkow 2014; Wang 2008). Tolerance and psychological and physical dependence may occur with prolonged use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use is not recommended in patients with severe liver disease (Health Canada 2018). Daily use of cannabis may be associated with moderate to severe fibrosis in patients with hepatitis C virus infection (Ishida 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use is not recommended in patients with severe kidney disease (Health Canada 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Adolescents and young adults: Regular use of cannabis products during adolescence and young adulthood may impair brain development and result in cognitive impairment (Volkow 2014). In addition, young patients who smoke cannabis are at a higher risk for adverse psychosocial effects (eg, suicidal ideation, illicit drug use, cannabis use disorder) (CFPC 2014; Gobbi 2019). Use in people &lt;25 years of age is not recommended (Health Canada 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• CYP2C9 polymorphism: THC is metabolized via CYP2C9 to 11-hydroxy-delta-9-THC, the major active metabolite (Dean 2020; Hryhorowicz 2018; Sachse-Seeboth 2009; Watanabe 2007; Syndros Canadian product monograph). According to dronabinol labeling, individuals with decreased CYP2C9 function have 2- to 3-fold times higher exposure than individuals with normal CYP2C9 function (Dronabinol prescribing information; Syndros Canadian product monograph).</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Older adults may be more sensitive to the neurological, psychoactive, and postural hypotensive effects of THC; use with caution (Dronabinol prescribing information; Syndros Canadian product monograph). Consider use of smaller initial doses.</p></div>
<div class="block prod-avail drugH1Div" id="F56544604"><span class="drugH1">Product Availability</span>
<p style="text-indent:-2em;margin-left:2em;">While cannabis is considered a Schedule I drug by the United States federal government, local state laws and regulations may differ. Refer to both federal and local laws for details.</p>
<p style="text-indent:-2em;margin-left:2em;">More information on state laws within the United States can be found here: http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx#3
                  </p>
<p style="text-indent:-2em;margin-left:2em;">Available formulations are not regulated by the US Food and Drug Administration (FDA) and may vary by location; available formulations may include but are not necessarily limited to dried cannabis flower, e-liquid cartridges, capsules, chewable candies (gummies), baked goods, beverages, oils, tinctures, sublingual sprays, tongue strips, lozenges, dabs, waxes, lotions, and ointments.</p></div>
<div class="block csi drugH1Div" id="F56544393"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-I</p>
<p style="text-indent:0em;">
<b>Note: </b>While cannabis is considered a Schedule I drug by the federal government of the United States, local state laws and regulations may differ. Refer to both federal and local laws for details.</p></div>
<div class="block accres drugH1Div" id="F56544391"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;">While cannabis is considered a Schedule I drug by the United States federal government, local state laws and regulations may differ. Refer to both federal and local laws for details.</p>
<p style="text-indent:0em;margin-top:2em;">More information on state laws within the United States can be found here: http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx#3
                  </p></div>
<div class="block off-label drugH1Div" id="F56544396"><span class="drugH1">Use: Off-Label: Adult</span><p>Anxiety (alternative or adjunctive agent); Inflammatory bowel disease (alternative adjunctive agent); Pain, chronic (alternative agent); Posttraumatic stress disorder (alternative agent); Spasticity secondary to multiple sclerosis (alternative agent)</p></div>
<div class="block cyt drugH1Div" id="F24180725"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C9 (major), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F24180722"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): Cannabis may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the tachycardic effect of Cannabinoid-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: May enhance the adverse/toxic effect of Cannabis. Specifically, the risk of hypoglycemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: Cannabis may increase the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the CNS depressant effect of Cannabinoid-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the tachycardic effect of Cannabinoid-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Substrates (High risk with Inducers): Cannabis may decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inhibitors (Moderate): May increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol serum concentrations may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be decreased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be decreased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propofol: Cannabis may diminish the therapeutic effect of Propofol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: Cannabinoid-Containing Products may enhance the tachycardic effect of Sympathomimetics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Cannabis may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the tachycardic effect of Cannabinoid-Containing Products. Blood pressure raising effects and drowsiness may also be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Cannabinoid-Containing Products may increase the serum concentration of Warfarin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F56544576"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> The AUC increases about 4-fold when oral cannabidiol is administered with a high-fat meal (Perucca 2020).</p></div>
<div class="block rep_considerations drugH1Div" id="F56544565"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Delta-9-tetrahydrocannabinol (THC), a main component of marijuana, may interfere with endogenous regulation of the male and female reproductive systems. THC activates cannabinoid receptors, which can be found in the uterus, ovaries, oviduct, follicles, sperm, and testis (Ezechukwu 2020). Marijuana exposure may lead to changes in semen parameters (including changes in sperm count, motility, morphology, and DNA fragmentation) and prolong the menstrual cycle, which could influence reproduction. However, available human studies evaluating the actual impact of cannabis on male and female fertility are inconclusive (Corsi 2021; Dubovis 2020; Harlow 2021; Mumford 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Until sufficient data become available, patients planning to become pregnant are encouraged to discontinue use of medical cannabis and use therapies with pregnancy-specific safety information (ACOG 2017).</p></div>
<div class="block pri drugH1Div" id="F56544566"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Delta-9-tetrahydrocannabinol (THC) crosses the placenta (NASEM 2017). The active metabolite, 11-hydroxy-tetrahydrocannabinol (11-OH-THC), can be detected in the umbilical cord (Metz 2019). In addition, cannabidiol, 11-OH-THC, and other metabolites can be detected in the meconium (Kim 2018).</p>
<p style="text-indent:0em;margin-top:2em;">THC activates cannabinoid receptors, which can be found in the placenta and uterus; exposure during pregnancy may lead to embryotoxic and fetotoxic effects (Ezechukwu 2020). THC is highly lipophilic, which leads to slow clearance from fetal tissues. Due to delayed clearance, fetal exposure may be prolonged after maternal discontinuation (Corsi 2021). Most pregnancy outcome data are from nonmedicinal exposure and may be confounded by concomitant use of tobacco, alcohol, and/or illicit substances. Quantification of maternal marijuana exposure is often self-reported (which may not reflect actual use), exposure is variable (route of administration, frequency of use), and the potency of marijuana has increased over time, limiting comparisons from earlier studies to current data (Bailey 2020; Coleman-Cowger 2018; Conner 2016; Corsi 2020; Grzeskowiak 2020; Gunn 2016; Howard 2019; Luke 2019; Metz 2017; Metz 2019; Metz 2022; Nawa 2020; Paul 2021; Peterson 2020; Sharapova 2018; Stroud 2018). In general, there may be an association with in-utero cannabis exposure and a risk for small gestational age, prematurity, low birthweight, and adverse neurobehavioral development (Dubovis 2020; Grant 2020; Nashed 2021). However, available information following maternal use of marijuana is unclear and insufficient to evaluate cannabis exposure on pregnancy outcomes (ACOG 2017; NASEM 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Use of medical cannabis has been evaluated for nausea and vomiting associated with chemotherapy, and some pregnant patients have reported use of marijuana for pregnancy-associated nausea and vomiting. However, use for this purpose cannot be recommended based on available information (Dickson 2018; Koren 2020; Westfall 2006).</p>
<p style="text-indent:0em;margin-top:2em;">There are no FDA-approved uses of medical cannabis for pregnant patients. Until sufficient safety data become available, pregnant patients are encouraged to discontinue use of medical cannabis and use therapies with pregnancy-specific safety information (ACOG 2017).</p>
<p style="text-indent:0em;margin-top:2em;">States with medical marijuana laws allowing medical cannabis or recreational use have seen an increased use by patients who are pregnant. Reviews highlight that increased availability does not imply safety for pregnancy. In addition, health care providers and patients should be aware of state specific laws related to reporting marijuana exposure in pregnant patients (Krening 2018; Meinhofer 2019; Miller 2019).</p></div>
<div class="block brc drugH1Div" id="F56544567"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Delta-9-tetrahydrocannabinol (THC) and the active metabolites 11-hydroxy-tetrahydrocannabinol (11-OH-THC) and 9-hydroxy-tetrahydrocannabinol (9-OH-THC) can be detected in breast milk following maternal inhalation of marijuana (Perez-Reyes 1982). THC and 11-OH-THC can also be detected in breast milk following maternal use of edible products (Moss 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">Reported breast milk concentrations of THC are highly variable and influenced by the frequency of maternal use and sampling time since last exposure (Bertrand 2018; Moss 2021). Cannabinoids are highly lipophilic and have a relatively low molecular weight, allowing for easy transfer into breast milk. The fat composition in breast milk is variable, which can also impact cannabinoid content (Corsi 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">A study evaluated the pharmacokinetics of medical cannabis in the breast milk of 8 women 3 to 5 months postpartum who were exclusively breastfeeding full-term infants. Breast milk was sampled prior to and between 20 minutes and 4 hours after inhalation of a specified product obtained from a single dispensary. Maximum concentrations of THC in breast milk occurred 1 hour after inhalation. Metabolites were not detected; however, a longer study period may be required to evaluate breast milk concentrations of 11-OH-THC and 9-OH-THC (Baker 2018). THC was measurable in breast milk 6 days following maternal use in 1 mother (Bertrand 2018). A second study suggests the half-life of THC in breast milk could be 17 days (Wymore 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">A case report notes the presence of 11-OH-THC and 9-OH-THC in a fecal sample of a breastfed infant following maternal use of inhaled marijuana, used daily for 8 months (Perez-Reyes 1982).</p>
<p style="text-indent:-2em;margin-left:2em;">Neurodevelopment may be impaired; however, studies evaluating infant development following exposure to cannabis via breast milk have conflicting outcomes. Outcome data are from nonmedicinal exposure and may be confounded by concomitant use of tobacco, alcohol, and/or illicit substances. Quantification of maternal marijuana exposure is self-reported (which may not reflect actual use), exposure is variable (route of administration, frequency of use), and the potency of marijuana has increased over time, limiting comparisons from earlier studies to current data. Maternal marijuana use may also be associated with a shorter duration of breastfeeding (Ordean 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">Limited guidance is available specific to the use of marijuana in breastfeeding patients due to variations in marijuana potency, differences in legal availability, and the wide range of maternal exposure in available studies. The Academy of Breastfeeding Medicine recommends use of marijuana be eliminated or reduced in patients who are breastfeeding. Patients using marijuana should be counseled that long-term neurobehavioral effects to a breastfed infant are possible. In addition, secondhand marijuana smoke may be associated with sudden infant death syndrome (ABM [Reece-Stremtan 2015]). Mothers should avoid coexposures of substances such as alcohol and tobacco and avoid breastfeeding within 1 hour of inhaled cannabis use (Ordean 2020). Until sufficient safety data become available, breastfeeding patients are encouraged to discontinue use of medical cannabis and use therapies with breastfeeding-specific safety information (ACOG 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">States with medical marijuana laws allowing medical cannabis or recreational use have seen an increased use by patients who are breastfeeding. Reviews highlight that increased availability does not imply safety for breastfeeding patients. In addition, health care providers and patients should be aware of state specific laws related to reporting marijuana exposure in breastfeeding patients (Krening 2018; Meinhofer 2019; Miller 2019)</p></div>
<div class="block mop drugH1Div" id="F56544602"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for adverse effects and cannabis use disorder (Busse 2021; CFPC 2014).</p></div>
<div class="block pha drugH1Div" id="F56544578"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Cannabis encompasses drugs and products produced from the plant <i>Cannabis sativa</i>. Although cannabis contains over 100 phytocannabinoids, the main active components include delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD); the specific concentration of each component will vary depending upon the specific product or strain, cultivation environment, and techniques used (Ebbert 2018). THC and CBD interact with the endocannabinoid system, including direct or indirect activation of type 1 (CB<sub>1</sub>) and type 2 (CB<sub>2</sub>) cannabinoid receptors. CB<sub>1</sub> receptors are found primarily in the CNS (especially in the prefrontal cortex, basal ganglia, hippocampus, amygdala, hypothalamus, and cerebellum), smooth muscle, myocardium, adipocytes, and preganglionic sympathetic neurons (Ebbert 2018). THC is a partial agonist at CB<sub>1</sub> receptors which results in the therapeutic and psychoactive effects of cannabis; CBD has week affinity for CB<sub>1</sub> receptors but may have indirect effects at these sites (Health Canada 2018; NASEM 2017). CB<sub>2</sub> receptors are found in peripheral blood mononuclear cells, natural killer cells, myocardium, vascular endothelium, smooth muscle mesenchymal-derived CNS microglia (Ebbert 2018); THC is an agonist at CB<sub>2</sub> receptors while CBD does not directly interact at these sites (NASEM 2017). In addition, CBD may exhibit activity at other targets (eg, ion channels, receptors, enzymes), which may be associated with therapeutic effects (Health Canada 2018).</p></div>
<div class="block phk drugH1Div" id="F56544579"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action (Health Canada 2018):</p>
<p style="text-indent:-2em;margin-left:4em;">Inhalation (smoking or vaporization): Rapid (Huestis 2007); within ~5 minutes (Health Canada 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 30 to 90 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Sublingual: 5 to 30 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect (Health Canada 2018):</p>
<p style="text-indent:-2em;margin-left:6em;">Inhalation (smoking or vaporization): 20 to 30 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 2 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Sublingual: 1.5 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration of action (Health Canada 2018):</p>
<p style="text-indent:-2em;margin-left:4em;">Inhalation (smoking or vaporization): 2 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 4 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Sublingual: 12 to 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption:</p>
<p style="text-indent:-2em;margin-left:4em;">Inhalation (smoking): Up to 25% to 27% with practical use (Health Canada 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Varied based on vehicle used to deliver the dose; following ingestion of delta-9-tetrahydrocannabinol (THC) added to a chocolate cookie, absorption was 4% to 12% (Ohlsson 1980).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: THC: 10 L/kg (Huestis 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 95% to 99% primarily to lipoproteins (Huestis 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP isoenzymes (2C9, 2C19, 2D6, and 3A4) (Sativex Canadian product monograph).</p>
<p style="text-indent:-2em;margin-left:4em;">THC: Primarily via CYP2C9 to an active metabolite (11-hydroxy-delta-9-THC) and CYP3A4 (Dean 2020; Watanabe 2007); undergoes significant first pass metabolism following oral administration (Perucca 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Cannabidiol (CBD): Hepatic via CYP isoenzymes to 7-hydroxy-cannabidiol (Sativex Canadian product monograph); undergoes significant first pass metabolism following oral administration (Huestis 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability:</p>
<p style="text-indent:-2em;margin-left:4em;">Inhalation (smoking): 2% to 56%. <b>Note: </b>Variability may be due to efficiency and method of smoking (Huestis 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Fasting: ~6%; Administration with a high fat meal: ~25% (Perucca 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Initial (plasma; prolonged with higher doses): CBD: ~5 to 9 hours; THC: ~2 to 5 hours (Sativex Canadian product monograph).</p>
<p style="text-indent:-2em;margin-left:4em;">Terminal: 24 to 36 hours (or longer) secondary to redistribution from fatty tissue (Sativex Canadian product monograph).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum:</p>
<p style="text-indent:-2em;margin-left:4em;">Inhalation (smoking): 9 minutes (Huestis 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 1 to 5 hours (Ohlsson 1980).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine and feces, primarily as metabolites (Huestis 2007).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-17296917">
<a name="17296917"></a>Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. <i>Neurology</i>. 2007;68(7):515-521. doi:10.1212/01.wnl.0000253187.66183.9c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/17296917/pubmed" id="17296917" target="_blank">17296917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28035196">
<a name="28035196"></a>Ahmed W, Katz S. Therapeutic use of cannabis in inflammatory bowel disease. <i>Gastroenterol Hepatol (N Y)</i>. 2016;12(11):668-679.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/28035196/pubmed" id="28035196" target="_blank">28035196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29449241">
<a name="29449241"></a>Allan GM, Ramji J, Perry D, et al. Simplified guideline for prescribing medical cannabinoids in primary care. <i>Can Fam Physician</i>. 2018;64(2):111-120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/29449241/pubmed" id="29449241" target="_blank">29449241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28937574">
<a name="28937574"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Committee Opinion No. 722: Marijuana use during pregnancy and lactation. <i>Obstet Gynecol</i>. 2017;130(4):e205-e209. doi:10.1097/AOG.0000000000002354<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/28937574/pubmed" id="28937574" target="_blank">28937574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26362106">
<a name="26362106"></a>Andreae MH, Carter GM, Shaparin N, et al. Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data. <i>J Pain</i>. 2015;16(12):1221-1232. doi:10.1016/j.jpain.2015.07.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/26362106/pubmed" id="26362106" target="_blank">26362106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32139807">
<a name="32139807"></a>Bailey BA, Wood DL, Shah D. Impact of pregnancy marijuana use on birth outcomes: results from two matched population-based cohorts. <i>J Perinatol</i>. 2020;40(10):1477-1482. doi:10.1038/s41372-020-0643-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/32139807/pubmed" id="32139807" target="_blank">32139807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29630019">
<a name="29630019"></a>Baker T, Datta P, Rewers-Felkins K, Thompson H, Kallem RR, Hale TW. Transfer of inhaled cannabis into human breast milk. <i>Obstet Gynecol</i>. 2018;131(5):783-788. doi:10.1097/AOG.0000000000002575<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/29630019/pubmed" id="29630019" target="_blank">29630019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25676540">
<a name="25676540"></a>Ball S, Vickery J, Hobart J, et al. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. <i>Health Technol Assess</i>. 2015;19(12):vii-viii, xxv-xxxi, 1-187. doi:10.3310/hta19120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/25676540/pubmed" id="25676540" target="_blank">25676540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21307846">
<a name="21307846"></a>Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. <i>Neuropsychopharmacology</i>. 2011;36(6):1219-1226. doi:10.1038/npp.2011.6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/21307846/pubmed" id="21307846" target="_blank">21307846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30150212">
<a name="30150212"></a>Bertrand KA, Hanan NJ, Honerkamp-Smith G, Best BM, Chambers CD. Marijuana use by breastfeeding mothers and cannabinoid concentrations in breast milk. <i>Pediatrics</i>. 2018;142(3):e20181076. doi:10.1542/peds.2018-1076<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/30150212/pubmed" id="30150212" target="_blank">30150212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24205805">
<a name="24205805"></a>Bonn-Miller MO, Boden MT, Bucossi MM, Babson KA. Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. <i>Am J Drug Alcohol Abuse</i>. 2014;40(1):23-30. doi:10.3109/00952990.2013.821477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/24205805/pubmed" id="24205805" target="_blank">24205805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34497062">
<a name="34497062"></a>Busse JW, Vankrunkelsven P, Zeng L, et al. Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. <i>BMJ</i>. 2021;374:n2040. doi:10.1136/bmj.n2040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/34497062/pubmed" id="34497062" target="_blank">34497062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29883744">
<a name="29883744"></a>Coleman-Cowger VH, Oga EA, Peters EN, Mark K. Prevalence and associated birth outcomes of co-use of Cannabis and tobacco cigarettes during pregnancy. <i>Neurotoxicol Teratol</i>. 2018;68:84-90. doi:10.1016/j.ntt.2018.06.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/29883744/pubmed" id="29883744" target="_blank">29883744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CFPC.1">
<a name="CFPC.1"></a>College of Family Physicians of Canada (CFPC). <i>Authorizing Dried Cannabis for Chronic Pain or Anxiety: Preliminary Guidance from the College of Family Physicians of Canada</i>. College of Family Physicians of Canada; 2014</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27607879">
<a name="27607879"></a>Conner SN, Bedell V, Lipsey K, Macones GA, Cahill AG, Tuuli MG. Maternal marijuana use and adverse neonatal outcomes: a systematic review and meta-analysis. <i>Obstet Gynecol</i>. 2016;128(4):713-723. doi:10.1097/AOG.0000000000001649<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/27607879/pubmed" id="27607879" target="_blank">27607879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22586334">
<a name="22586334"></a>Corey-Bloom J, Wolfson T, Gamst A, et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. <i>CMAJ</i>. 2012;184(10):1143-1150. doi:10.1503/cmaj.110837<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/22586334/pubmed" id="22586334" target="_blank">22586334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32778828">
<a name="32778828"></a>Corsi DJ, Donelle J, Sucha E, et al. Maternal cannabis use in pregnancy and child neurodevelopmental outcomes. <i>Nat Med</i>. 2020;26(10):1536-1540. doi:10.1038/s41591-020-1002-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/32778828/pubmed" id="32778828" target="_blank">32778828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33998877">
<a name="33998877"></a>Corsi DJ, Murphy MSQ, Cook J. The effects of cannabis on female reproductive health across the life course. <i>Cannabis Cannabinoid Res</i>. 2021;6(4):275-287. doi:10.1089/can.2020.0065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/33998877/pubmed" id="33998877" target="_blank">33998877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20829306">
<a name="20829306"></a>Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. <i>J Psychopharmacol</i>. 2011;25(1):121-130. doi:10.1177/0269881110379283<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/20829306/pubmed" id="20829306" target="_blank">20829306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31522966">
<a name="31522966"></a>Davenport S. Price and product variation in Washington's recreational cannabis market. <i>Int J Drug Policy</i>. 2021;91:102547. doi:10.1016/j.drugpo.2019.08.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/31522966/pubmed" id="31522966" target="_blank">31522966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33211456">
<a name="33211456"></a>Dean L, Kane M. Dronabinol Therapy and CYP2C9 Genotype. In: Pratt VM, Scott SA, Pirmohamed M, et al, eds. Medical Genetics Summaries [Internet]. National Center for Biotechnology Information (US); 2012. Published November 17, 2020. <a href="https://www.ncbi.nlm.nih.gov/books/NBK564166/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK564166/</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/33211456/pubmed" id="33211456" target="_blank">33211456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26178655">
<a name="26178655"></a>Decuyper I, Ryckebosch H, Van Gasse AL, et al. Cannabis allergy: what do we know anno 2015. <i>Arch Immunol Ther Exp (Warsz)</i>. 2015;63(5):327-332. doi:10.1007/s00005-015-0352-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/26178655/pubmed" id="26178655" target="_blank">26178655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25533893">
<a name="25533893"></a>Degenhardt L, Lintzeris N, Campbell G, et al. Experience of adjunctive cannabis use for chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study. <i>Drug Alcohol Depend</i>. 2015;147:144-150. doi:10.1016/j.drugalcdep.2014.11.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/25533893/pubmed" id="25533893" target="_blank">25533893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32879596">
<a name="32879596"></a>Desmarais A, Smiddy S, Reddy S, El-Dallal M, Erlich J, Feuerstein JD. Evidence supporting the benefits of marijuana for Crohn's disease and ulcerative colitis is extremely limited: a meta-analysis of the literature. <i>Ann Gastroenterol</i>. 2020;33(5):495-499. doi:10.20524/aog.2020.0516<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/32879596/pubmed" id="32879596" target="_blank">32879596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29742676">
<a name="29742676"></a>Dickson B, Mansfield C, Guiahi M, et al. Recommendations from cannabis dispensaries about first-trimester cannabis use. <i>Obstet Gynecol</i>. 2018;131(6):1031-1038. doi:10.1097/AOG.0000000000002619<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/29742676/pubmed" id="29742676" target="_blank">29742676</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Dronabinol [prescribing information]. Piscataway, NJ: Camber Pharmaceuticals Inc; May 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32315745">
<a name="32315745"></a>Dubovis M, Muneyyirci-Delale O. Effects of marijuana on human reproduction. <i>Reprod Toxicol</i>. 2020;94:22-30. doi:10.1016/j.reprotox.2020.04.071<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/32315745/pubmed" id="32315745" target="_blank">32315745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30522595">
<a name="30522595"></a>Ebbert JO, Scharf EL, Hurt RT. Medical cannabis. <i>Mayo Clin Proc</i>. 2018;93(12):1842-1847. doi:10.1016/j.mayocp.2018.09.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/30522595/pubmed" id="30522595" target="_blank">30522595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31945038">
<a name="31945038"></a>Ellington S, Salvatore PP, Ko J, et al; Lung Injury Response Epidemiology/Surveillance Task Force. Update: product, substance-use, and demographic characteristics of hospitalized patients in a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury - United States, August 2019-January 2020. <i>MMWR Morb Mortal Wkly Rep</i>. 2020;69(2):44-49. doi:10.15585/mmwr.mm6902e2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/31945038/pubmed" id="31945038" target="_blank">31945038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18688212">
<a name="18688212"></a>Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. <i>Neuropsychopharmacology</i>. 2009;34(3):672-680. doi:10.1038/npp.2008.120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/18688212/pubmed" id="18688212" target="_blank">18688212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32744098">
<a name="32744098"></a>Ezechukwu HC, Diya CA, Shrestha N, Hryciw DH. Role for endocannabinoids in early pregnancy: recent advances and the effects of cannabis use.<i> Am J Physiol Endocrinol Metab</i>. 2020;319(3):E557-E561. doi:10.1152/ajpendo.00210.2020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/32744098/pubmed" id="32744098" target="_blank">32744098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26886465">
<a name="26886465"></a>Franz CA, Frishman WH. Marijuana use and cardiovascular disease. <i>Cardiol Rev</i>. 2016;24(4):158-162. doi:10.1097/CRD.0000000000000103<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/26886465/pubmed" id="26886465" target="_blank">26886465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16552618">
<a name="16552618"></a>Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). <i>Int Urogynecol J Pelvic Floor Dysfunct</i>. 2006;17(6):636-641. doi:10.1007/s00192-006-0086-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/16552618/pubmed" id="16552618" target="_blank">16552618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34137450">
<a name="34137450"></a>Gianotti RJ, Cheifetz AS. Cannabis and inflammatory bowel disease: all smoke and mirrors? <i>J Crohns Colitis</i>. 2021;15(11):1785-1786. doi:10.1093/ecco-jcc/jjab091<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/34137450/pubmed" id="34137450" target="_blank">34137450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30758486">
<a name="30758486"></a>Gobbi G, Atkin T, Zytynski T, et al. Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: a systematic review and meta-analysis. <i>JAMA Psychiatry</i>. 2019;76(4):426-434. doi:10.1001/jamapsychiatry.2018.4500<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/30758486/pubmed" id="30758486" target="_blank">30758486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32770666">
<a name="32770666"></a>Grant KS, Conover E, Chambers CD. Update on the developmental consequences of cannabis use during pregnancy and lactation.<i> Birth Defects Res</i>. 2020;112(15):1126-1138. doi:10.1002/bdr2.1766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/32770666/pubmed" id="32770666" target="_blank">32770666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24830188">
<a name="24830188"></a>Greer GR, Grob CS, Halberstadt AL. PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. <i>J Psychoactive Drugs</i>. 2014;46(1):73-77. doi:10.1080/02791072.2013.873843<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/24830188/pubmed" id="24830188" target="_blank">24830188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32452049">
<a name="32452049"></a>Grzeskowiak LE, Grieger JA, Andraweera P, et al. The deleterious effects of cannabis during pregnancy on neonatal outcomes. <i>Med J Aust</i>. 2020;212(11):519-524. doi:10.5694/mja2.50624<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/32452049/pubmed" id="32452049" target="_blank">32452049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27048634">
<a name="27048634"></a>Gunn JK, Rosales CB, Center KE, et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. <i>BMJ Open</i>. 2016;6(4):e009986. doi:10.1136/bmjopen-2015-009986<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/27048634/pubmed" id="27048634" target="_blank">27048634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26560314">
<a name="26560314"></a>Gurney J, Shaw C, Stanley J, Signal V, Sarfati D. Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis. <i>BMC Cancer</i>. 2015;15:897. doi:10.1186/s12885-015-1905-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/26560314/pubmed" id="26560314" target="_blank">26560314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33165011">
<a name="33165011"></a>Harlow AF, Wesselink AK, Hatch EE, Rothman KJ, Wise LA. Male preconception marijuana use and spontaneous abortion: a prospective cohort study. <i>Epidemiology</i>. 2021;32(2):239-247. doi:10.1097/EDE.0000000000001303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/33165011/pubmed" id="33165011" target="_blank">33165011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30074291">
<a name="30074291"></a>Häuser W, Finn DP, Kalso E, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. <i>Eur J Pain</i>. 2018a;22(9):1547-1564. doi:10.1002/ejp.1297<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/30074291/pubmed" id="30074291" target="_blank">30074291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29034533">
<a name="29034533"></a>Häuser W, Petzke F, Fitzcharles MA. Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management - an overview of systematic reviews. <i>Eur J Pain</i>. 2018b;22(3):455-470. doi:10.1002/ejp.1118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/29034533/pubmed" id="29034533" target="_blank">29034533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HealthCanada.1">
<a name="HealthCanada.1"></a>Health Canada. Information for health care professionals: cannabis (marihuana, marijuana) and the cannabinoids. <a href="https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/information-medical-practitioners/information-health-care-professionals-cannabis-cannabinoids.html" target="_blank">https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/information-medical-practitioners/information-health-care-professionals-cannabis-cannabinoids.html</a>. Published October 2018. Accessed September 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26103031">
<a name="26103031"></a>Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. <i>JAMA</i>. 2015;313(24):2474-2483. doi:10.1001/jama.2015.6199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/26103031/pubmed" id="26103031" target="_blank">26103031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32197092">
<a name="32197092"></a>Hindley G, Beck K, Borgan F, et al. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. <i>Lancet Psychiatry</i>. 2020;7(4):344-353. doi:10.1016/S2215-0366(20)30074-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/32197092/pubmed" id="32197092" target="_blank">32197092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30908346">
<a name="30908346"></a>Howard DS, Dhanraj DN, Devaiah CG, Lambers DS. Cannabis use based on urine drug screens in pregnancy and its association with infant birth weight.<i> J Addict Med</i>. 2019;13(6):436-441. doi:10.1097/ADM.0000000000000516<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/30908346/pubmed" id="30908346" target="_blank">30908346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28534260">
<a name="28534260"></a>Hryhorowicz S, Walczak M, Zakerska-Banaszak O, Słomski R, Skrzypczak-Zielińska M. Pharmacogenetics of cannabinoids. <i>Eur J Drug Metab Pharmacokinet</i>. 2018;43(1):1-12. doi:10.1007/s13318-017-0416-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/28534260/pubmed" id="28534260" target="_blank">28534260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25587109">
<a name="25587109"></a>Huang YH, Zhang ZF, Tashkin DP, Feng B, Straif K, Hashibe M. An epidemiologic review of marijuana and cancer: an update. <i>Cancer Epidemiol Biomarkers Prev</i>. 2015;24(1):15-31. doi:10.1158/1055-9965.EPI-14-1026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/25587109/pubmed" id="25587109" target="_blank">25587109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17712819">
<a name="17712819"></a>Huestis MA. Human cannabinoid pharmacokinetics. <i>Chem Biodivers</i>. 2007;4(8):1770-1804. doi:10.1002/cbdv.200790152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/17712819/pubmed" id="17712819" target="_blank">17712819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18166478">
<a name="18166478"></a>Ishida JH, Peters MG, Jin C, et al. Influence of cannabis use on severity of hepatitis C disease. <i>Clin Gastroenterol Hepatol</i>. 2008;6(1):69-75. doi:10.1016/j.cgh.2007.10.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/18166478/pubmed" id="18166478" target="_blank">18166478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34473850">
<a name="34473850"></a>Kawka M, Erridge S, Holvey C, et al. Clinical outcome data of first cohort of chronic pain patients treated with cannabis-based sublingual oils in the United Kingdom: analysis from the UK Medical Cannabis Registry.<i> J Clin Pharmacol</i>. 2021;61(12):1545-1554. doi:10.1002/jcph.1961<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/34473850/pubmed" id="34473850" target="_blank">34473850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12011290">
<a name="12011290"></a>Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. <i>Neurology</i>. 2002;58(9):1404-1407. doi:10.1212/wnl.58.9.1404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/12011290/pubmed" id="12011290" target="_blank">12011290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28948698">
<a name="28948698"></a>Kim J, de Castro A, Lendoiro E, Cruz-Landeira A, López-Rivadulla M, Concheiro M. Detection of in utero cannabis exposure by umbilical cord analysis. <i>Drug Test Anal</i>. 2018;10(4):636-643. doi:10.1002/dta.2307<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/28948698/pubmed" id="28948698" target="_blank">28948698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33526133">
<a name="33526133"></a>Koren G, Cohen R. The use of cannabis for hyperemesis gravidarum (HG). <i>J Cannabis Res</i>. 2020;2(1):4. doi:10.1186/s42238-020-0017-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/33526133/pubmed" id="33526133" target="_blank">33526133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29373417">
<a name="29373417"></a>Krening C, Hanson K. Marijuana-perinatal and legal issues with use during pregnancy. <i>J Perinat Neonatal Nurs</i>. 2018;32(1):43-52. doi:10.1097/JPN.0000000000000303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/29373417/pubmed" id="29373417" target="_blank">29373417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31971931">
<a name="31971931"></a>Krishnasamy VP, Hallowell BD, Ko JY, et al; Lung Injury Response Epidemiology/Surveillance Task Force. Update: characteristics of a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury - United States, August 2019-January 2020. <i>MMWR Morb Mortal Wkly Rep</i>. 2020;69(3):90-94. doi:10.15585/mmwr.mm6903e2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/31971931/pubmed" id="31971931" target="_blank">31971931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30744979">
<a name="30744979"></a>Luke S, Hutcheon J, Kendall T. Cannabis use in pregnancy in British Columbia and selected birth outcomes.<i> J Obstet Gynaecol Can</i>. 2019;41(9):1311-1317. doi:10.1016/j.jogc.2018.11.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/30744979/pubmed" id="30744979" target="_blank">30744979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31106499">
<a name="31106499"></a>Meinhofer A, Witman A, Murphy SM, Bao Y. Medical marijuana laws are associated with increases in substance use treatment admissions by pregnant women. <i>Addiction</i>. 2019;114(9):1593-1601. doi:10.1111/add.14661<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/31106499/pubmed" id="31106499" target="_blank">31106499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28578174">
<a name="28578174"></a>Metz TD, Allshouse AA, Hogue CJ, et al. Maternal marijuana use, adverse pregnancy outcomes, and neonatal morbidity. <i>Am J Obstet Gynecol</i>. 2017;217(4):478.e1-478.e8. doi:10.1016/j.ajog.2017.05.050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/28578174/pubmed" id="28578174" target="_blank">28578174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34142398">
<a name="34142398"></a>Metz TD, McMillin GA, Silver RM, et al. Quantification of prenatal marijuana use: evaluation of the correlation between self-report, serum, urine and umbilical cord assays among women delivering at two urban Colorado hospitals. <i>Addiction</i>. 2022;117(1):172-181. doi: 0.1111/add.15606<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/34142398/pubmed" id="34142398" target="_blank">34142398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30531577">
<a name="30531577"></a>Metz TD, Silver RM, McMillin GA, et al. Prenatal marijuana use by self-report and umbilical cord sampling in a state with marijuana legalization. <i>Obstet Gynecol</i>. 2019;133(1):98-104. doi:10.1097/AOG.0000000000003028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/30531577/pubmed" id="30531577" target="_blank">30531577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30511088">
<a name="30511088"></a>Miller J. Ethical issues arising from marijuana use by nursing mothers in a changing legal and cultural context. <i>HEC Forum</i>. 2019;31(1):11-27. doi:10.1007/s10730-018-9368-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/30511088/pubmed" id="30511088" target="_blank">30511088</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11401936">
<a name="11401936"></a>Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. <i>Circulation</i>. 2001;103(23):2805-2809. doi:10.1161/01.cir.103.23.2805<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/11401936/pubmed" id="11401936" target="_blank">11401936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27551883">
<a name="27551883"></a>Mizrachi Zer-Aviv T, Segev A, Akirav I. Cannabinoids and post-traumatic stress disorder: clinical and preclinical evidence for treatment and prevention. <i>Behav Pharmacol</i>. 2016;27(7):561-569. doi:10.1097/FBP.0000000000000253<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/27551883/pubmed" id="27551883" target="_blank">27551883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33469174">
<a name="33469174"></a>Moss MJ, Bushlin I, Kazmierczak S, et al. Cannabis use and measurement of cannabinoids in plasma and breast milk of breastfeeding mothers. <i>Pediatr Res</i>. 2021;90(4):861-868. doi:10.1038/s41390-020-01332-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/33469174/pubmed" id="33469174" target="_blank">33469174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29513392">
<a name="29513392"></a>Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. <i>Cochrane Database Syst Rev</i>. 2018;3(3):CD012182. doi:10.1002/14651858.CD012182.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/29513392/pubmed" id="29513392" target="_blank">29513392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33421071">
<a name="33421071"></a>Mumford SL, Flannagan KS, Radoc JG, et al. Cannabis use while trying to conceive: a prospective cohort study evaluating associations with fecundability, live birth and pregnancy loss. <i>Hum Reprod</i>. 2021;36(5):1405-1415. doi:10.1093/humrep/deaa355<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/33421071/pubmed" id="33421071" target="_blank">33421071</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23648372">
<a name="23648372"></a>Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. <i>Clin Gastroenterol Hepatol</i>. 2013;11(10):1276-1280.e1. doi:10.1016/j.cgh.2013.04.034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/23648372/pubmed" id="23648372" target="_blank">23648372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24969296">
<a name="24969296"></a>Naftali T, Mechulam R, Lev LB, Konikoff FM. Cannabis for inflammatory bowel disease. <i>Dig Dis</i>. 2014;32(4):468-474. doi:10.1159/000358155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/24969296/pubmed" id="24969296" target="_blank">24969296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28349233">
<a name="28349233"></a>Naftali T, Mechulam R, Marii A, et al. Low-dose cannabidiol is safe but not effective in the treatment for Crohn's disease, a randomized controlled trial. <i>Dig Dis Sci</i>. 2017;62(6):1615-1620. doi:10.1007/s10620-017-4540-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/28349233/pubmed" id="28349233" target="_blank">28349233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31567639">
<a name="31567639"></a>Naftali T, Bar-Lev Schleider L, Sklerovsky Benjaminov F, Lish I, Konikoff FM, Ringel Y. Medical cannabis for inflammatory bowel disease: real-life experience of mode of consumption and assessment of side-effects. <i>Eur J Gastroenterol Hepatol</i>. 2019;31(11):1376-1381. doi:10.1097/MEG.0000000000001565<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/31567639/pubmed" id="31567639" target="_blank">31567639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33519564">
<a name="33519564"></a>Nashed MG, Hardy DB, Laviolette SR. Prenatal cannabinoid exposure: emerging evidence of physiological and neuropsychiatric abnormalities. <i>Front Psychiatry</i>. Published online January 14, 2021. doi:10.3389/fpsyt.2020.624275<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/33519564/pubmed" id="33519564" target="_blank">33519564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28182367">
<a name="28182367"></a>National Academies of Sciences, Engineering, and Medicine (NASEM). <i>The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research</i>. The National Academies Press; 2017. doi:10.17226/24625 <i></i>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/28182367/pubmed" id="28182367" target="_blank">28182367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NCSL.1">
<a name="NCSL.1"></a>National Conferance of State Legislatures (NCSL). State Medical Cannabis Laws. https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx#1. Accessed Septermber 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32602574">
<a name="32602574"></a>Nawa N, Garrison-Desany HM, Kim Y, et al. Maternal persistent marijuana use and cigarette smoking are independently associated with shorter gestational age. <i>Paediatr Perinat Epidemiol</i>. 2020;34(6):696-705. doi:10.1111/ppe.12686<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/32602574/pubmed" id="32602574" target="_blank">32602574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34321302">
<a name="34321302"></a>Noori A, Miroshnychenko A, Shergill Y, et al. Opioid-sparing effects of medical cannabis or cannabinoids for chronic pain: a systematic review and meta-analysis of randomised and observational studies. <i>BMJ Open</i>. 2021;11(7):e047717. doi:10.1136/bmjopen-2020-047717<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/34321302/pubmed" id="34321302" target="_blank">34321302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6250760">
<a name="6250760"></a>Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. <i>Clin Pharmacol Ther</i>. 1980;28(3):409-416. doi:10.1038/clpt.1980.181<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/6250760/pubmed" id="6250760" target="_blank">6250760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31992503">
<a name="31992503"></a>Ordean A, Kim G. Cannabis use during lactation: literature review and clinical recommendations. <i>J Obstet Gynaecol Can</i>. 2020;42(10):1248-1253. doi:10.1016/j.jogc.2019.11.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/31992503/pubmed" id="31992503" target="_blank">31992503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27458286">
<a name="27458286"></a>Paice JA, Portenoy R, Lacchetti C, et al. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2016;34(27):3325-3345. doi:10.1200/JCO.2016.68.5206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/27458286/pubmed" id="27458286" target="_blank">27458286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32965490">
<a name="32965490"></a>Paul SE, Hatoum AS, Fine JD, et al. Associations between prenatal cannabis exposure and childhood outcomes: results from the ABCD study. <i>JAMA Psychiatry</i>. 2021;78(1):64-76. doi:10.1001/jamapsychiatry.2020.2902<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/32965490/pubmed" id="32965490" target="_blank">32965490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6287261">
<a name="6287261"></a>Perez-Reyes M, Wall ME. Presence of delta9-tetrahydrocannabinol in human milk. <i>N Engl J Med</i>. 1982;307(13):819-820. doi:10.1056/NEJM198209233071311<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/6287261/pubmed" id="6287261" target="_blank">6287261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32504461">
<a name="32504461"></a>Perucca E, Bialer M. Critical aspects affecting cannabidiol oral bioavailability and metabolic elimination, and related clinical implications. <i>CNS Drugs</i>. 2020;34(8):795-800. doi:10.1007/s40263-020-00741-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/32504461/pubmed" id="32504461" target="_blank">32504461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32539126">
<a name="32539126"></a>Peterson BS, Rosen T, Dingman S, et al. Associations of maternal prenatal drug abuse with measures of newborn brain structure, tissue organization, and metabolite concentrations. <i>JAMA Pediatr</i>. 2020;174(9):831-842. doi:10.1001/jamapediatrics.2020.1622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/32539126/pubmed" id="32539126" target="_blank">32539126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32162103">
<a name="32162103"></a>Rabinak CA, Blanchette A, Zabik NL, et al. Cannabinoid modulation of corticolimbic activation to threat in trauma-exposed adults: a preliminary study. <i>Psychopharmacology (Berl)</i>. 2020;237(6):1813-1826. doi:10.1007/s00213-020-05499-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/32162103/pubmed" id="32162103" target="_blank">32162103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32842985">
<a name="32842985"></a>Raymundi AM, da Silva TR, Sohn JMB, Bertoglio LJ, Stern CA. Effects of ∆<sup>9</sup>-tetrahydrocannabinol on aversive memories and anxiety: a review from human studies. <i>BMC Psychiatry</i>. 2020;20(1):420. doi:10.1186/s12888-020-02813-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/32842985/pubmed" id="32842985" target="_blank">32842985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25836677">
<a name="25836677"></a>Reece-Stremtan S, Marinelli KA. ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015. <i>Breastfeed Med</i>. 2015;10(3):135-141. doi:10.1089/bfm.2015.9992<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/25836677/pubmed" id="25836677" target="_blank">25836677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935052">
<a name="24935052"></a>Roitman P, Mechoulam R, Cooper-Kazaz R, Shalev A. Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder. <i>Clin Drug Investig</i>. 2014;34(8):587-591. doi:10.1007/s40261-014-0212-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/24935052/pubmed" id="24935052" target="_blank">24935052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26874461">
<a name="26874461"></a>Rumalla K, Reddy AY, Mittal MK. Recreational marijuana use and acute ischemic stroke: a population-based analysis of hospitalized patients in the United States.<i> J Neurol Sci</i>. 2016;364:191-196. doi:10.1016/j.jns.2016.01.066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/26874461/pubmed" id="26874461" target="_blank">26874461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19005461">
<a name="19005461"></a>Sachse-Seeboth C, Pfeil J, Sehrt D, et al. Interindividual variation in the pharmacokinetics of delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. <i>Clin Pharmacol Ther</i>. 2009;85(3):273-276. doi:10.1038/clpt.2008.213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/19005461/pubmed" id="19005461" target="_blank">19005461</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sativex (delta-9-tetrahydrocannabinol [THC] and cannabidiol [CBD]) [product monograph]. Histon, Cambridge, United Kingdom: GW Pahrma Ltd; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30624194">
<a name="30624194"></a>Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in anxiety and sleep: a large case series. <i>Perm J</i>. 2019;23:18-41. doi:10.7812/TPP/18-041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/30624194/pubmed" id="30624194" target="_blank">30624194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30335203">
<a name="30335203"></a>Sharapova SR, Phillips E, Sirocco K, Kaminski JW, Leeb RT, Rolle I. Effects of prenatal marijuana exposure on neuropsychological outcomes in children aged 1-11 years: a systematic review. <i>Paediatr Perinat Epidemiol</i>. 2018;32(6):512-532. doi:10.1111/ppe.12505<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/30335203/pubmed" id="30335203" target="_blank">30335203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28000146">
<a name="28000146"></a>Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA. Cannabinoid hyperemesis syndrome: diagnosis, pathophysiology, and treatment-a systematic review.<i> J Med Toxicol</i>. 2017;13(1):71-87. doi:10.1007/s13181-016-0595-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/28000146/pubmed" id="28000146" target="_blank">28000146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28245077">
<a name="28245077"></a>Steenkamp MM, Blessing EM, Galatzer-Levy IR, Hollahan LC, Anderson WT. Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: a literature review. <i>Depress Anxiety</i>. 2017;34(3):207-216. doi:10.1002/da.22596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/28245077/pubmed" id="28245077" target="_blank">28245077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34480749">
<a name="34480749"></a>Stella B, Baratta F, Della Pepa C, Arpicco S, Gastaldi D, Dosio F. Cannabinoid formulations and delivery systems: current and future options to treat pain. <i>Drugs</i>. 2021;81(13):1513-1557. doi:10.1007/s40265-021-01579-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/34480749/pubmed" id="34480749" target="_blank">34480749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29847469">
<a name="29847469"></a>Stockings E, Campbell G, Hall WD, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. <i>Pain</i>. 2018;159(10):1932-1954. doi:10.1097/j.pain.0000000000001293<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/29847469/pubmed" id="29847469" target="_blank">29847469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24407485">
<a name="24407485"></a>Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease. <i>Inflamm Bowel Dis</i>. 2014;20(3):472-480. doi:10.1097/01.MIB.0000440982.79036.d6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/24407485/pubmed" id="24407485" target="_blank">24407485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30266574">
<a name="30266574"></a>Stroud LR, Papandonatos GD, McCallum M, Kehoe T, Salisbury AL, Huestis MA. Prenatal tobacco and marijuana co-use: impact on newborn neurobehavior.<i> Neurotoxicol Teratol</i>. 2018;70:28-39. doi:10.1016/j.ntt.2018.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/30266574/pubmed" id="30266574" target="_blank">30266574</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Syndros (dronabinol) [product monograph]. Chandler, AZ: Benuvia Therapeutics Inc; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32923663">
<a name="32923663"></a>Takakuwa KM, Hergenrather JY, Shofer FS, Schears RM. The impact of medical cannabis on intermittent and chronic opioid users with back pain: how cannabis diminished prescription opioid usage. <i>Cannabis Cannabinoid Res</i>. 2020a;5(3):263-270. doi:10.1089/can.2019.0039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/32923663/pubmed" id="32923663" target="_blank">32923663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33409086">
<a name="33409086"></a>Takakuwa KM, Sulak D. A survey on the effect that medical cannabis has on prescription opioid medication usage for the treatment of chronic pain at three medical cannabis practice sites. <i>Cureus</i>. 2020b;12(12):e11848. doi:10.7759/cureus.11848<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/33409086/pubmed" id="33409086" target="_blank">33409086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23802821">
<a name="23802821"></a>Tashkin DP. Effects of marijuana smoking on the lung. <i>Ann Am Thorac Soc</i>. 2013;10(3):239-247. doi:10.1513/AnnalsATS.201212-127FR<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/23802821/pubmed" id="23802821" target="_blank">23802821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30646241">
<a name="30646241"></a>Torres-Moreno MC, Papaseit E, Torrens M, Farré M. Assessment of efficacy and tolerability of medicinal cannabinoids in patients with multiple sclerosis: a systematic review and meta-analysis. <i>JAMA Netw Open</i>. 2018;1(6):e183485. doi:10.1001/jamanetworkopen.2018.3485<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/30646241/pubmed" id="30646241" target="_blank">30646241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15327040">
<a name="15327040"></a>Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. <i>Mult Scler</i>. 2004;10(4):417-424. doi:10.1191/1352458504ms1048oa<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/15327040/pubmed" id="15327040" target="_blank">15327040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24897085">
<a name="24897085"></a>Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. <i>N Engl J Med</i>. 2014;370(23):2219-2227. doi:10.1056/NEJMra1402309<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/24897085/pubmed" id="24897085" target="_blank">24897085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18073554">
<a name="18073554"></a>Wallace M, Schulteis G, Atkinson JH, et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. <i>Anesthesiology</i>. 2007;107(5):785-796. doi:10.1097/01.anes.0000286986.92475.b7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/18073554/pubmed" id="18073554" target="_blank">18073554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25843054">
<a name="25843054"></a>Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH. Efficacy of inhaled cannabis on painful diabetic neuropathy. <i>J Pain</i>. 2015;16(7):616-627. doi:10.1016/j.jpain.2015.03.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/25843054/pubmed" id="25843054" target="_blank">25843054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18559804">
<a name="18559804"></a>Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. <i>CMAJ</i>. 2008;178(13):1669-1678. doi:10.1503/cmaj.071178<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/18559804/pubmed" id="18559804" target="_blank">18559804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17303175">
<a name="17303175"></a>Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. <i>Life Sci</i>. 2007;80(15):1415-1419. doi:10.1016/j.lfs.2006.12.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/17303175/pubmed" id="17303175" target="_blank">17303175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16401527">
<a name="16401527"></a>Westfall RE, Janssen PA, Lucas P, Capler R. Survey of medicinal cannabis use among childbearing women: patterns of its use in pregnancy and retroactive self-assessment of its efficacy against 'morning sickness'. <i>Complement Ther Clin Pract</i>. 2006;12(1):27-33. doi:10.1016/j.ctcp.2005.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/16401527/pubmed" id="16401527" target="_blank">16401527</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26103030">
<a name="26103030"></a>Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. <i>JAMA.</i> 2015;313(24):2456-2473. doi:10.1001/jama.2015.6358<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/26103030/pubmed" id="26103030" target="_blank">26103030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25767748">
<a name="25767748"></a>Wilkinson ST, Radhakrishnan R, D'Souza DC. Impact of cannabis use on the development of psychotic disorders.<i> Curr Addict Rep</i>. 2014;1(2):115-128. doi:10.1007/s40429-014-0018-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/25767748/pubmed" id="25767748" target="_blank">25767748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27621666">
<a name="27621666"></a>Wilsey BL, Deutsch R, Samara E, et al. A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis. <i>J Pain Res</i>. 2016;9:587-598. doi:10.2147/JPR.S113138<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/27621666/pubmed" id="27621666" target="_blank">27621666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33683306">
<a name="33683306"></a>Wymore EM, Palmer C, Wang GS, et al. Persistence of Δ-9-tetrahydrocannabinol in human breast milk. <i>JAMA Pediatr</i>. 2021;175(6):632-634. doi:10.1001/jamapediatrics.2020.6098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/33683306/pubmed" id="33683306" target="_blank">33683306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31793418">
<a name="31793418"></a>Xu DH, Cullen BD, Tang M, Fang Y. The effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities. <i>Curr Pharm Biotechnol</i>. 2020;21(5):390-402. doi:10.2174/1389201020666191202111534<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/31793418/pubmed" id="31793418" target="_blank">31793418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25467189">
<a name="25467189"></a>Yadav V, Narayanaswami P. Complementary and alternative medical therapies in multiple sclerosis--the American Academy of Neurology guidelines: a commentary. <i>Clin Ther</i>. 2014;36(12):1972-1978. doi:10.1016/j.clinthera.2014.10.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/25467189/pubmed" id="25467189" target="_blank">25467189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26644963">
<a name="26644963"></a>Yarnell S. The use of medicinal marijuana for posttraumatic stress disorder: a review of the current literature. <i>Prim Care Companion CNS Disord</i>. 2015;17(3):10.4088/PCC.15r01786. doi:10.4088/PCC.15r01786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/26644963/pubmed" id="26644963" target="_blank">26644963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14615106">
<a name="14615106"></a>Zajicek J, Fox P, Sanders H, et al; UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. <i>Lancet</i>. 2003;362(9395):1517-1526. doi:10.1016/S0140-6736(03)14738-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/14615106/pubmed" id="14615106" target="_blank">14615106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zuardi.1">
<a name="Zuardi.1"></a>Zuardi AW, de Souza Crippa JA, Hallak JEC, Campos AC, Guimarães FS. The anxiolytic effects of cannabidiol (CBD). In: <i>Handbook of Cannabis and Related Pathologies. </i> Academic Press; 2017:e131-e139.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34085149">
<a name="34085149"></a>Zylla DM, Eklund J, Gilmore G, et al. A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction. <i>Support Care Cancer</i>. 2021;29(12):7471-7478. doi:10.1007/s00520-021-06301-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medical-cannabis-drug-information/abstract-text/34085149/pubmed" id="34085149" target="_blank">34085149</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 134930 Version 15.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
